Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus
Open Access
- 19 December 2015
- journal article
- case report
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 5 (1) , 81-87
Abstract
Introduction Few studies have investigated the effect of increased creatinine clearance (CrCl) on linezolid (LZD) concentration. Herein, we report the pharmacokinetic/pharmacodynamic (PK/PD) profile of LZD used in the management of methicillin-resistant Staphylococcus aureus (MRSA) pneumonia with concomitant bacteremia in a patient with high CrCl caused by diabetes insipidus (DI). Case Report A 19-year-old man was admitted to the intensive care unit following a traumatic brain injury. After admission, he underwent a craniotomy for the severe brain injury. However, he developed DI after the operation. Despite treatment with vasopressin, his urine output reached 5–6 L/day as a result of the DI, and his CrCl increased to 180–278 mL/min. We were required to administer 6–7 L of fluid a day to compensate for the high urinary fluid output. On day 55, MRSA pneumonia with sepsis was suspected and, consequently, LZD was administrated intravenously (600 mg every 12 h). He was treated with LZD for 14 days. The patient has since successfully recovered from MRSA pneumonia with concomitant bacteremia, and was transferred to the general ward on day 82. Blood LZD levels from days 60–68, which were measured after the patient’s transfer to the general ward, showed that the trough levels were lower than the threshold level of detection. The blood 24-h area under the plasma LZD concentration–time curve (AUC)24/minimum inhibitory concentration (MIC) was 69.3. Conclusion In spite of the low level of LZD AUC24/MIC caused by the high CrCl with DI, MRSA pneumonia with concomitant bacteremia was successfully treated with LZD.Keywords
This publication has 17 references indexed in Scilit:
- A simple high‐performance liquid chromatography for the determination of linezolid in human plasma and salivaBiomedical Chromatography, 2015
- Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational studyCritical Care, 2014
- Plasma exposure of free linezolid and its ratio to minimum inhibitory concentration varies in critically ill patientsInternational Journal of Antimicrobial Agents, 2013
- Clinical update on linezolid in the treatment of Gram-positive bacterial infectionsInfection and Drug Resistance, 2012
- Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]The International Journal of Tuberculosis and Lung Disease, 2012
- Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled StudyClinical Infectious Diseases, 2012
- Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases PharmacistsAmerican Journal of Health-System Pharmacy, 2009
- Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2003
- Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.2001
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981